Jacqueline K. Barton's most recent trade in Gilead Sciences, Inc. was a trade of 6,809 Non-qualified Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 7, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences | Jacqueline K. Barton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2025 | 6,809 | 6,809 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Jacqueline K. Barton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2025 | 1,516 | 26,056 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Jacqueline K. Barton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 12,648 | 12,648 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Jacqueline K. Barton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 2,310 | 24,540 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Jacqueline K. Barton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 10,173 | 10,173 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Jacqueline K. Barton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 1,887 | 22,230 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Jacqueline K. Barton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2022 | 15,851 | 15,851 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Jacqueline K. Barton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2022 | 2,444 | 20,343 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Jacqueline K. Barton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2022 | 2,223 | 17,899 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Jacqueline K. Barton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2022 | 2,223 | 4,553 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Jacqueline K. Barton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 14,665 | 14,665 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Jacqueline K. Barton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 2,223 | 6,776 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Jacqueline K. Barton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2021 | 1,936 | 4,553 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Jacqueline K. Barton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2021 | 1,936 | 15,676 (0%) | 0% | - | Common Stock |